The Cancer Prevention and Research Institute of Texas has awarded eight grants totaling more than $13 million dedicated to expanding access to cancer clinical trials in Texas, including one new award that will strengthen clinical trial network infrastructure, two first-of-their-kind CPRIT awards to encourage increased participation in clinical trials and five awards that support the next generation of promising clinical investigators.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
